Literature DB >> 32098730

Exploring Variation in the Use of Conservative Management for Low-risk Prostate Cancer in the Veterans Affairs Healthcare System.

Stacy Loeb1, Nataliya K Byrne2, Binhuan Wang3, Danil V Makarov4, Daniel Becker5, David R Wise6, Herbert Lepor7, Dawn Walter4.   

Abstract

Current guidelines recommend conservative management as the preferred option for most low-risk prostate cancer cases, with certain possible exceptions (age <55yr, African Americans, and high-volume grade group 1). Although previous studies have documented substantial heterogeneity in the uptake of conservative management, less is known about the underlying reason for this variation and whether it is due to guideline-concordant factors (age, race, and biopsy cancer volume). We explored variation in the use of conservative management for low-risk prostate cancer among 20 597 men diagnosed in the US Veterans Affairs health care system from 2010 to 2016. Conservative management increased substantially over this time from 51% to 76% (p< 0.001). However, there was substantial variation by facility (35-100%). Multivariable analysis revealed that patient factors included in the guidelines (e.g., age and biopsy cores), other patient factors (eg, marital status and PSA) and non-patient factors (eg, geographic region, case volume, year) were associated with conservative management use. In conclusion, even within an integrated health care system, there remains significant heterogeneity in the uptake of conservative management for low-risk prostate cancer. Both guideline-concordant factors and other factors not discussed in the guidelines were associated with conservative management use. PATIENT
SUMMARY: In the US Veterans Affairs health care system the vast majority of men with low-risk prostate cancer were managed conservatively by 2016, although there was significant variation by facility. Patient factors specifically mentioned in guidelines had the greatest impact on prediction of conservative management. Published by Elsevier B.V.

Entities:  

Keywords:  Active surveillance; Conservative management; Prostate cancer; Veterans; Watchful waiting

Year:  2020        PMID: 32098730      PMCID: PMC7250727          DOI: 10.1016/j.eururo.2020.02.004

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  7 in total

1.  The Association Between Evaluation at Academic Centers and the Likelihood of Expectant Management in Low-risk Prostate Cancer.

Authors:  Nataniel H Lester-Coll; Henry S Park; Charles E Rutter; Christopher D Corso; Brandon R Mancini; Debra N Yeboa; Simon P Kim; Cary P Gross; James B Yu
Journal:  Urology       Date:  2016-07-05       Impact factor: 2.649

2.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.

Authors:  Matthew R Cooperberg; Peter R Carroll
Journal:  JAMA       Date:  2015-07-07       Impact factor: 56.272

3.  Practice- vs Physician-Level Variation in Use of Active Surveillance for Men With Low-Risk Prostate Cancer: Implications for Collaborative Quality Improvement.

Authors:  Gregory B Auffenberg; Brian R Lane; Susan Linsell; Michael L Cher; David C Miller
Journal:  JAMA Surg       Date:  2017-10-01       Impact factor: 14.766

4.  Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015.

Authors:  Stacy Loeb; Nataliya Byrne; Danil V Makarov; Herbert Lepor; Dawn Walter
Journal:  JAMA       Date:  2018-06-05       Impact factor: 56.272

5.  Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer.

Authors:  Christopher P Filson; Florian R Schroeck; Zaojun Ye; John T Wei; Brent K Hollenbeck; David C Miller
Journal:  J Urol       Date:  2014-02-08       Impact factor: 7.450

6.  Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.

Authors:  Ronald C Chen; R Bryan Rumble; D Andrew Loblaw; Antonio Finelli; Behfar Ehdaie; Matthew R Cooperberg; Scott C Morgan; Scott Tyldesley; John J Haluschak; Winston Tan; Stewart Justman; Suneil Jain
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

7.  Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.

Authors:  Stacy Loeb; Yasin Folkvaljon; Caitlin Curnyn; David Robinson; Ola Bratt; Pär Stattin
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

  7 in total
  3 in total

1.  Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone.

Authors:  James Steven Wysock; Ezequiel Becher; Rozalba Gogaj; Nermarie Velazquez; Herbert Lepor
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-07-07       Impact factor: 5.554

2.  Prostate Cancer Screening Guidelines for Black Men: Spotlight on an Empty Stage.

Authors:  Ruth Etzioni; Yaw A Nyame
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 13.506

3.  Variation in the Use of Active Surveillance for Low-Risk Prostate Cancer Across US Census Regions.

Authors:  Bashir Al Hussein Al Awamlh; Neal Patel; Xiaoyue Ma; Adam Calaway; Lee Ponsky; Jim C Hu; Jonathan E Shoag
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.